- Home
- NAMS
as 07-26-2024 4:00pm EST
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
| Founded: | 2019 | Country: | Netherlands |
| Employees: | N/A | City: | NARRDEN |
| Market Cap: | 1.7B | IPO Year: | N/A |
| Target Price: | $33.25 | AVG Volume (30 days): | 211.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.63 - $26.35 | Next Earning Date: | 03-31-2023 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 340.04% | Revenue Growth (next year): | -84.62% |
Latest NewAmsterdam Pharma Company N.V. News
NAMS Breaking Stock News: Dive into NAMS Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 hours ago
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
GlobeNewswire
9 days ago
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
GlobeNewswire
19 days ago
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
GlobeNewswire
23 days ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
Compare NAMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAMS NewAmsterdam Pharma Company N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.